Success Metrics

Clinical Success Rate

100.0%

Based on 9 completed trials

Completion Rate

100%(9/9)

Active Trials

2(18%)

Results Posted

89%(8 trials)

Phase Distribution

Ph phase_2

Ph phase_1

55%

Ph phase_3

18%

Ph phase_4

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Early Phase 1First-in-human

1(9.1%)

Phase 1Safety & dosage

6(54.5%)

Phase 2Efficacy & side effects

1(9.1%)

Phase 3Large-scale testing

2(18.2%)

Phase 4Post-market surveillance

1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(9)

Detailed Status

Completed9

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (9.1%)

Phase 16 (54.5%)

Phase 21 (9.1%)

Phase 32 (18.2%)

Phase 41 (9.1%)

Trials by Status

active_not_recruiting218%

completed982%

Recent Activity

2 active trials

Showing 5 of 11

active_not_recruitingphase_2

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

NCT04703322

active_not_recruitingphase_3

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

NCT04488822

completedphase_1

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

NCT02401815

completedphase_4

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704

completedphase_3

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

NCT02371369

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT04703322Phase 2

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active Not Recruiting

NCT04488822Phase 3

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

Active Not Recruiting

NCT02401815Phase 1

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Completed

NCT04526704Phase 4

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Completed

NCT02371369Phase 3

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Completed

NCT02734433Phase 1

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Completed

NCT02777710Phase 1

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

Completed

NCT04223635Early Phase 1

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Completed

NCT03291288Phase 1

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Completed

NCT03158103Phase 1

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Completed

NCT03138759Phase 1

Effect of Probenecid on Pexidartinib Pharmacokinetics